Provident Co of the Employees of the Hebrew University LTD Cuts Stake in Moderna, Inc. (NASDAQ:MRNA)

Provident Co of the Employees of the Hebrew University LTD lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 20.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,113 shares of the company’s stock after selling 4,097 shares during the quarter. Moderna accounts for approximately 0.8% of Provident Co of the Employees of the Hebrew University LTD’s holdings, making the stock its 27th biggest position. Provident Co of the Employees of the Hebrew University LTD’s holdings in Moderna were worth $669,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MRNA. Knuff & Co LLC boosted its stake in Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after purchasing an additional 244 shares during the last quarter. Allworth Financial LP boosted its position in shares of Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after buying an additional 281 shares during the last quarter. Howard Capital Management Inc. raised its position in Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after buying an additional 297 shares during the last quarter. Larson Financial Group LLC raised its position in Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares during the last quarter. Finally, Empowered Funds LLC boosted its holdings in shares of Moderna by 6.6% during the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company’s stock valued at $347,000 after acquiring an additional 322 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 0.9 %

NASDAQ:MRNA opened at $34.62 on Monday. The business’s 50-day moving average is $35.94 and its 200 day moving average is $47.15. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The company has a market capitalization of $13.36 billion, a P/E ratio of -3.73 and a beta of 1.86.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Citigroup began coverage on shares of Moderna in a report on Thursday. They set a “neutral” rating and a $40.00 price objective for the company. Piper Sandler reissued an “overweight” rating and set a $69.00 price target (down from $115.00) on shares of Moderna in a report on Monday, November 18th. JPMorgan Chase & Co. set a $45.00 price objective on Moderna in a report on Friday, February 14th. Morgan Stanley lowered their target price on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Finally, Berenberg Bank boosted their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus target price of $59.60.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.